Joshua Pinto insider trades: Neumora Therapeutics (NMRA) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Joshua reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | NMRA | ↓ Sell | 5,967 | $3.54 | $21K | Direct | Feb 19, 2026 (2d) |
| Feb 18, 2025 | NMRA | ↓ Sell | 8,048 | $1.67 | $13K | Direct | Feb 20, 2025 (2d) |
| Aug 27, 2024 | NMRA | ↓ Sell | 15,693 | $11.39 | $179K | Indirect | Aug 27, 2024 (0d) |
| Aug 26, 2024 | NMRA | ↓ Sell | 84,307 | $11.67 | $984K | Indirect | Aug 26, 2024 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NMRA insiders
Open-market trades in the last 12 months
About Joshua Pinto's insider trades
Joshua Pinto is President & CEO at Neumora Therapeutics (NMRA). Since Aug 26, 2024, Joshua has reported no open-market purchases and 4 sales worth $1.2M on SEC Form 4. In the last 12 months: 1 sale ($21K).
Their filings also include grants and awards (6 filings), shares returned to the company (3 filings), gifts (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NMRA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.